On Aug. 31, 2021, SK bioscience and GlaxoSmithKline announced the initiation of a Phase 3 clinical study of SKﾒs COVID-19 vaccine candidate, GBP510, in combination with GSKﾒs pandemic adjuvant following positive interim Phase 1/2 results.

The randomised, active-controlled global trial planned to enrol around 4,000 participants from a range of countries and will aim to evaluate GBP510ﾒs safety and immunogenicity compared to an active comparator – the AstraZeneca/Oxford University COVID-19 vaccine. The study was one of the first global Phase 3 trials to compare two different COVID-19 vaccine candidates.